Astellas appoints Takahiko Iwaya, former Sanofi executive, as Chief Strategy Officer to drive growth of new drug Vyloy.
Leadership Transition Amid Patent Expiry Crisis
Astellas Pharma faces a serious financial cliff as the patent for its blockbuster prostate‑cancer therapy Xtandi (generic name enzalutamide) begins to expire in 2026. Xtandi generated ¥960.8 billion (approximately $6.2 billion) in revenue in fiscal year 2025 alone, but it is confronting price reductions under the U.S. Inflation Reduction Act (IRA) and intense competition from rival drugs. In response, Astellas swiftly reorganized its leadership to fill the void left by the resignation of long‑time Chief Strategy Officer Adam Pearson. During the interim, Peter Sandor, Head of Corporate Strategy, acted as acting CSO, and the company has now appointed Takahiko Iwaya, formerly of Sanofi Japan, as its permanent Chief Strategy Officer effective July 1 2026.
Rationale for Recruiting a Multinational Pharma Strategist
The newly appointed Takahiko Iwaya is a leading global healthcare strategist who previously served as President and CEO of Sanofi Japan and as Chair of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan. He brings extensive hands‑on experience in coordinating localization strategies for multinational pharma companies in Asia and Japan and navigating complex pricing‑regulation environments. Astellas selected him as a multi‑purpose asset to accelerate early commercialization of its global pipeline while strengthening its position in the Japanese market. His insight into both multinational decision‑making structures and local regulatory requirements is expected to dramatically accelerate Astellas’s new‑drug launch pace.
Accelerating the Five Core New‑Drug Portfolio
As CSO, Iwaya will devote all resources to growing Astellas’s five Strategic Brands that are intended to fill the revenue gap left by Xtandi. The portfolio includes the Nectin‑4‑targeted antibody‑drug conjugate Padcev (generic name enfortumab vedotin) and the Claudin‑18.2‑targeted gastric‑cancer therapy Vyloy (generic name zolbetuximab). It also comprises the age‑related macular degeneration treatment Izervay (generic name avacincaptad pegol) and the menopause‑symptom therapy Veozah (generic name fezolinetant), each carrying a critical mandate to maximize market penetration. In fiscal year 2025, combined sales of these new drugs grew 43 % year‑over‑year to ¥480.3 billion, and growth is expected to accelerate under Iwaya’s leadership.
Outlook for Global Partnerships and M&A Expansion
In addition to anchoring its Strategic Brands in the market, Astellas is actively pursuing external innovation and strategic alliances to maximize R&D efficiency. As CSO, Iwaya will leverage the global network he built at Sanofi to substantially expand M&A and worldwide co‑development partnership opportunities. For example, following Astellas’s 2023 acquisition of Iveric Bio for $5.9 billion, which secured Izervay, the company will accelerate the build‑out of a pipeline of follow‑on deals to sustain mid‑ to long‑term growth. This approach will help Astellas establish a differentiated portfolio competitiveness amid strong rivals such as Johnson & Johnson’s Erleada (generic name apalutamide) and Pfizer’s Nubeqa (generic name darolutamide).
This appointment is a strategic move to address the patent expiry of Xtandi, which generates ¥960.8 billion in annual sales, by driving commercialization of key new drugs such as Padcev and Vyloy. In the short term, Astellas will pursue revenue diversification through global regulatory approvals and market entry of Izervay and Veozah. Over the medium to long term, accelerating growth of the five global Strategic Brands will help the company mitigate the anticipated financial impact after fiscal year 2026 and sustain annual sales growth. Moreover, Iwaya’s network, cultivated at Sanofi, is expected to facilitate additional M&A and the introduction of promising pipelines, such as the Iveric Bio acquisition. This will serve as a turning point for advancing next‑generation assets into early‑stage marketing to counter the aggressive advances of prostate‑cancer rivals like Erleada and Nubeqa.
Source: FierceBiotech (rss)